PerkinElmer has named Karl Hecker the new director of R&D for its Boston-based Center of Excellence, the company said this week.
Hecker joins PerkinElmer from Invitrogen and brings more then 20 years of scientific experience in chemistry and biochemistry applications, PerkinElmer said. He holds a PhD in biochemistry from Florida State University, a MS in chemistry from Eastern Illinois University, and master's and BS degrees in chemistry from Johann Wolfgang Goethe University, Frankfurt, Germany.
Galapagos named David Stone and Geoff McMillan to its non-executive board this week.
Stone is currently chairman of Cambridge Biostability and non-executive chairman of Cambridge Sensors. He has previously held positions at Galapagos unit BioFocus (of which he is a founder) and Wellcome Research Labs.
McMillan is non-executive director of Maelor. He has had positions at BioFocus and Elan and served on the board of Xenova Group and Roche's pharmaceutical division.
Mary Lipscomb was elected chairman of the board of directors of the National Center for Genome Resources, the NCGR announced this week. Lipscomb's position was effective Nov. 19, 2005, according to the statement.
Lipscomb is chair of the University of New Mexico's department of pathology. She replaces Miguel Rios, who was appointed chairman emeritus.
In addition, NCGR announced the elections to the board of the following: Donald Armstrong, member emeritus of Memorial Sloan-Kettering Cancer Center; Charles Arntzen, co-director of the Center for Infectious Diseases and Vaccinology at Arizona State University; William Beavis, chief scientific officer of NCGR; Michael Cawley, president and CEO of the Samuel Roberts Noble Foundation in Ardmore, Okla; Mark Chandler, chairman and CEO of Biophysical Corp., in Austin; Keith Joiner, dean of University of Arizona's college of medicine; Stuart Kauffman, director of the Institute for Biocomplexity and Informatics at the University of Calgary; Stephen Kingsmore, CEO of NCGR; Teresa Leger de Fernandez of Nordhaus Law Firm in Santa Fe; Rick Lyons of University of New Mexico's Center for Infectious Disease and Immunity; Michael Martin, president of New Mexico State University in Las Cruces, N.M.; Marvin Miller, chairman of Onconova Therapeutics in Livingston, NJ; Van Romero, vice president for research at New Mexico Tech in Socorro, NM; Gloria Sarto, director of the University of Wisconsin Center for Women's Health; Jon Soderstrom, managing director of the Office of Cooperative Research at Yale University; and Terry Yates, vice president or research and economic development at the University of New Mexico.
Charles River Laboratories said this week that it has named John Ho as senior vice president of corporate strategy.
Ho most recently served as a partner at Accenture's health and life sciences practice. Prior to this, Ho spent five years as a partner in the life science industry group of Pittiglio Rabin Todd & McGrath. He holds an MBA from the Amos Tuck School at Dartmouth College and an MD from Brown University School of Medicine.
CyBio is launching CyBi-Cellight, its scalable workstation for flash-luminescence screening, the company said this week.
CyBi-Cellight integrates the CyBi-Lumax flash reader, the CyBi-Well vario pipettor with stackers, plate handling, optional incubators, and CyBi-Drop non-contact dispensers. It is an all-in-one workstation that covers the screening lab workflow from plate replication, cell seeding, assay preparation, to final reading, CyBio said. The platform provides assays in 96-, 384-, and 1,536-well plates.
NovaScreen this week launched KinaseAdvisor, a screening panel of 48 protein kinase assays. According to NovaScreen, KinaseAdvisor is the most sensitive assay panel available for kinases. NovaScreen performs KinaseAdvisor assays on the Caliper LabChip 3000 platform, which uses electrophoresis instead of antibodies as the basis of the assay.
Peakdale said this week that it has released G6, the sixth and final release of its peakexplorer G-Protein Coupled Receptor library of screening compounds. The release now brings the total collection to 6,500 fully characterized compounds, Peakdale said.
Sigma-Aldrich said this week that it has released a new version of its Mission TRC shRNA human and mouse libraries.
According to the company, the libraries now carry about 65,000 shRNA vector constructs targeting 9,500 human genes and 3,400 mouse genes.
The newly added libraries include extensive coverage of the druggable genome and other highly studied targets, Sigma-Aldrich said.